We are live on ! Find out more
PCM

Puissance Capital Management Portfolio holdings

AUM $17.3M
1-Year Est. Return 149.36%
This Fund
S&P 500
This Quarter Est. Return
-39.47%
1 Year Est. Return
+149.36%
3 Year Est. Return
+115.5%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$87.7M
AUM Growth
-$55.6M
Cap. Flow
+$4.45M
Cap. Flow %
5.08%
Top 10 Hldgs %
100%
Holding
7
New
2
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CRVS icon
Corvus Pharmaceuticals
CRVS
+$1.94M
2
KDMN
Kadmon Holdings, Inc.
KDMN
+$1.71M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$805K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Technology 29.04%
2 Healthcare 15.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRAY
1
DELISTED
ViewRay, Inc.
VRAY
$41.5M 47.38%
6,842,975
– –
CHRN
2
ChronoScale Holdings
CHRN
$3.12B
$25.5M 29.04%
91,266
– –
KDMN
3
DELISTED
Kadmon Holdings, Inc.
KDMN
$9.36M 10.68%
4,499,352
+677,302
+18% +$1.71M
BLPH
4
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$6.65M 7.59%
553,250
– –
TCON
5
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$2.9M 3.31%
23,009
– –
CRVS icon
6
Corvus Pharmaceuticals
CRVS
$1.1B
$1.04M 1.19%
+284,869
New +$1.94M
XBI icon
7
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$716K 0.82%
+9,986
New +$805K

Similar funds

FM
Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return
IAM
ICM Asset Management Spokane, Washington $18.1M AUM 30.29% 1-Year Est. Return
FP
FFL Partners San Francisco, California $16.1M AUM 46.91% 1-Year Est. Return
AF
AMG Funds Stamford, Connecticut $20M AUM 3.75% 1-Year Est. Return
TCS
Texas Children's Houston, Texas $20.5M AUM 51.2% 1-Year Est. Return
JJ
JDC-JSC New York $20.8M AUM 30.94% 1-Year Est. Return
PCM
Proxima Capital Management New York $21M AUM 3.49% 1-Year Est. Return
NC
Numen Capital London, United Kingdom $13.5M AUM 47.6% 1-Year Est. Return

Puissance Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, Puissance Capital Management held 7 positions worth $87.7M, down 39% from $143M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Puissance Capital Management deployed $4.45M of net new capital in Q4 2018, opening 2 new positions and adding to 1 existing holding. Its largest new stake was Corvus Pharmaceuticals: 284,869 shares worth $1.04M.

By sector, the portfolio is most concentrated in Technology at 29% of assets, down from 34% a quarter earlier, followed by Healthcare.

  • Puissance Capital Management's largest Q4 2018 buy was Corvus Pharmaceuticals: 284,869 shares worth $1.04M.
  • Puissance Capital Management added most to Kadmon Holdings, Inc. in Q4 2018, an estimated $1.71M increase.
  • Puissance Capital Management's ten largest holdings make up 100% of its $87.7M portfolio in Q4 2018.
  • Puissance Capital Management opened 2 new positions and closed 0 in Q4 2018.
  • Puissance Capital Management's portfolio value fell 39% quarter-over-quarter to $87.7M.

Based on Puissance Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.